Abstract:Objective: To evaluate the safety and long-term efficacy of melphalan (Mel) instead of cyclophosphamide (Cy) in the modified busulfan/cyclophosphamide (Bu/Cy) regimen as a novel myeloablative conditioning regimen for patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Methods: The clinical data of 76 patients with acute myeloid leukemia undergoing allogeneic HSCT from November 2007 to October 2011 were retrospectively analyzed, of which 32 patients received Bu +Mel +Fludarabine(Flu) +Cytarabine(Ara-C) （BMFA）regimen（Bu 3.2mg· kg-1 · d-1 by vein, -8, -7,-6d; Mel 140mg·m-2·d-1, -5d; Flu 30mg·m-2·d-1，-4, -3, -2d; Ara-C 2g·m-2·d-1. -4, -3, -2d）, 44 cases received Bu+ Cy +Flu +Ara-C（BCFA）as modified Bu/Cy regimen (Bu 3.2mg· kg-1 · d-1 by vein, -9,-8, -7d; Cy 50mg· kg-1· d-1，-6, -5d; Flu 30mg·m-2·d-1，-4, -3, -2d; Ara-C 2g·m-2·d-1. -4, -3, -2d ). Anti-thymocyte globulin (ATG) was added to the haploid transplantation and unrelated donor transplant conditioning regimen. Both groups of patients have treated with Cyclosporine A (CsA)/ Tacrolimus (FK506) + short-course methotrexate (MTX)±mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prevention. Regimen-related toxicity, engraftment rates, GVHD, and Long-term outcome including relapse, non-relapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) were compared between the two groups. Results: Both groups of patients achieved neutrophil engraftment after transplantation. The incidence of grade Ⅲ-Ⅳ° oral mucositis and diarrhea in the BMFA group was higher than in the BCFA group (P=0.016, P=0.028). The incidence of Ⅱ~Ⅳ° acute GVHD in the BMFA group was also higher than in the BCFA group (37.5% vs. 15.9%，P=0.032). There was no significant difference in the incidence of chronic GVHD between the two groups. With a median follow-up of 97.5 months (2-131months), the cumulative incidence of relapse at 100 months in the BMFA group was lower than in the BCFA group (9.37% vs. 27.7%, P=0.055), and the incidence of NRM in BMFA group was 31.7% and 13.8% in BCFA group (P=0.076)．The OS were (59.0±8.8)% and(59.7±7.6)% (P=0.778)， and DFS were((58.7±8.8)％ and(60.0±7.5)％ (P=0.786) were comparable between BMFA group and BCFA group. In the BMFA group， univariate analysis showed that III-IV° oral mucositis，III-IV° diarrhea, and II-IV°aGVHD were risk factors for NRM (P values, 0.015, 0.015, 0.006, respectively), multivariate analysis showed that II~IV°aGVHD was an independent risk factor for NRM（P=0.025）. Conclusion: The conditioning regimen of melphalan instead of cyclophosphamide for allogeneic HSCT of acute myeloid leukemia has a low relapse rate. In the long-term follow-up, DFS and OS were similar to those of the modified Bu/Cy regimen. However, the prevention of regimen-related toxicity and the treatment and intervention of acute GVHD should be considered to reduce non-relapse mortality. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients

A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia

Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT

Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after "Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor'' with Standard Graft Versus Host Disease Prophylaxis after "10/10 HLA Matched Relative Donor'' Transplant

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant

High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Combination of Mycophenolate Mofetil with Cyclosporine A and Methotrexate As Gvhd Prophylaxis in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

Unrelated donor transplantation with post-transplant cyclophosphamide versus ATG for myelodysplastic neoplasms

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis

Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis

Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft-versus-host disease prophylaxis following allogeneic haemopoietic cell transplantation

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT